Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.